MPMatthias Pfister

Matthias Pfister

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matthias Pfister has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global benchmarks for minimally invasive right hemicolectomy for cancer

    by Fariba Abbassi, Michaela Ramser, Matthias Pfister, Roxane D Staiger, Sun J Kim, Ji W Park, Bart C T van de Laar, Marcos Gonzalez, Vittoria Perano, Georgette Camilleri, et al.


  • Immunonutrition in minimally invasive major abdominal surgery: A systematic review and meta-analysis of randomized clinical trials

    by Matthias Pfister, Nadja von Massow, Eva Kalkum, Pia Antony, Alexander Dullenkopf, Fabian Hauswirth, Pietro Renzulli, Markus K. Muller, Pascal Probst


  • Benefits of multi-day ex situ perfusion include dampened ischemia reperfusion injury in liver transplantation

    by Florian Huwyler, Matthias Pfister, Jonas Binz, Mark W. Tibbitt, Pierre-Alain Clavien


  • Open Access

    Glucose controls lipolysis through Golgi PtdIns4P-mediated regulation of ATGL

    by Lianggong Ding, Florian Huwyler, Fen Long, Wu Yang, Jonas Binz, Kendra Wernlé, Matthias Pfister, Manuel Klug, Miroslav Balaz, Barbara Ukropcova, et al.

    Metabolic crosstalk of the major nutrients glucose, amino acids and fatty acids (FAs) ensures systemic metabolic homeostasis. The coordination between the supply of glucose and FAs to meet various physiological demands is especially important as improper nutrient levels lead to metabolic disorders, such as diabetes and metabolic dysfunction-associated steatohepatitis (MASH). In response to the oscillations in blood glucose levels, lipolysis is thought to be mainly regulated hormonally to control FA liberation from lipid droplets by insulin, catecholamine and glucagon. However, whether general cell-intrinsic mechanisms exist to directly modulate lipolysis via glucose sensing remains largely unknown. Here we report the identification of such an intrinsic mechanism, which involves Golgi PtdIns4P-mediated regulation of adipose triglyceride lipase (ATGL)-driven lipolysis via intracellular glucose sensing. Mechanistically, depletion of intracellular glucose results in lower Golgi PtdIns4P levels, and thus reduced assembly of the E3 ligase complex CUL7FBXW8 in the Golgi apparatus. Decreased levels of the E3 ligase complex lead to reduced polyubiquitylation of ATGL in the Golgi and enhancement of ATGL-driven lipolysis. This cell-intrinsic mechanism regulates both the pool of intracellular FAs and their extracellular release to meet physiological demands during fasting and glucose deprivation. Moreover, genetic and pharmacological manipulation of the Golgi PtdIns4P–CUL7FBXW8–ATGL axis in mouse models of simple hepatic steatosis and MASH, as well as during ex vivo perfusion of a human steatotic liver graft leads to the amelioration of steatosis, suggesting that this pathway might be a promising target for metabolic dysfunction-associated steatotic liver disease and possibly MASH.


  • Open Access

    Screening for mitochondrial function before use-routine liver assessment during hypothermic oxygenated perfusion impacts liver utilization

    by Janina Eden, Eva Breuer, Dominique Birrer, Matteo Müller, Matthias Pfister, Hemma Mayr, Keyue Sun, Jeannette Widmer, Florian Huwyler, Udo Ungethüm, et al.


  • Open Access

    The Anniversary Study – 20 years of Clavien-Dindo Classification & 10 years of Comprehensive Complication Index® v1

    by Fariba Abbassi, Matthias Pfister, Anja Domenghino, Milo A Puhan, Pierre-A. Clavien

    Outcome reporting of surgical procedures was revolutionized in 2004 with the introduction of the Clavien-Dindo (CD) classification.1 This 5-scale grading system offers an objective, simple, reliable, and reproducible way of recording complications, and has gained wide acceptance among the international surgical community. With over 27’000 citations the original paper has become the most cited article in the surgical literature. In 2013, another milestone in surgical outcome reporting was introduced, the Comprehensive Complication Index (CCI®).2 The CCI® is based on the Clavien-Dindo system and is the first metric, which captures the entire postoperative morbidity as a numeric scale from 0-100 from the day of surgery until most complications are expected to have occurred or beyond. Both systems have gained wide acceptance and are routinely used in many centers. However, users have been challenged with many questions over the years mostly on how to rank some postoperative events. Now, after 20 and 10 years of working with these two well established outcome reporting systems, it is time for a critical evaluation.

  • Open Access

    The Role of Late-Onset Inflammatory Markers in the Prediction of Complications and Graft Survival after Pancreas Transplantation

    by Sandro Hügli, Philip C. Müller, Matthias Pfister, Fabian Rössler

    Background: Despite great progress in graft survival and complication rates, pronounced inflammatory responses are common after pancreas transplantation (PT). Subsequent to the first postoperative increase in inflammatory markers, we have frequently observed a second peak of C-reactive protein (CRP) and white blood cells (WBCs) following PT. This analysis is to assess the incidence and clinical relevance of late-onset increases in inflammatory markers following PT. Materials and methods: We analyzed all consecutive PTs over a 20-year period. The second peak of CRP (SCP) and WBCs (SWP) was defined as an increase >3 days after PT subsequent to a relevant initial decrease. Results: Of 116 patients, 60 (51.7%) developed SCP. SCP was not associated with pancreas graft loss or with thrombosis at discharge or at 90 days after PT (6.7% vs. 0.0%, p = 0.1; 8.3% vs. 1.8%, p = 0.2; and 15.0% vs. 3.6%, p = 0.06, respectively). Patients with SCP had more complications overall at discharge and at 90 days (85.0% vs. 50.0%, p < 0.001 and 93.3% vs. 76.8%, p = 0.02). In multivariable analysis, SCP was significantly associated with pre-transplant HbA1c (OR 2.1 (95% CI: 1.3–3.8); p = 0.005) and female gender (OR 0.03 (95% CI: 0.004–0.14); p ≤ 0.001). No significant association was found between SCP and pancreas cold ischemia time (OR 1.0 (95% CI: 1.0–1.0); p = 0.1), donor age (OR 1.01 (95% CI: 0.96–1.06); p = 0.7), recipient age (OR 0.9 (95% CI: 0.9–1.0); p = 0.1), or recipient BMI (OR 0.9 (95% CI: 0.9–1.4); p = 0.3). SWP did not differ in patients with or without SCP (p = 0.07) and there was no correlation with pancreas graft loss or relaparotomy (p = 0.3 and p = 0.6, respectively). Insulin-free graft survival after 1, 5, and 10 years did not differ between patients with SCP and those without SCP (95.0%, 90.2%, 90.2% vs. 96.1%, 91.2%, 88.7%, respectively; p = 0.964). Conclusion: Late-onset inflammatory reactions are frequently seen in PT and are correlated with higher overall complication rates. They are not correlated, however, with graft-specific complications or insulin-free graft survival.